

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1           1 (currently amended): A method for screening identifying a compound for an  
2 ability to modulate that modulates helicase-dependent p53-mediated apoptosis comprising:  
3           (a) providing a biologically active p53 polypeptide, and a helicase  
4 polypeptide, wherein the helicase is selected from the group consisting of XPB and XPD,  
5           (b) contacting a compound suspected of inducing helicase- dependent p53-  
6 mediated apoptosis with the polypeptides of step (a)  
7           (c) detecting whether or not the compound is capable of specifically inhibiting  
8 binding of the p53 polypeptide to the helicase, wherein a compound that specifically inhibits the  
9 binding of the p53 polypeptide to the helicase is a compound that modulates helicase- dependent  
10 p53-mediated apoptosis.

2-15 (canceled)

1           16 (previously presented): The method of claim 1, further comprising contacting  
2 the polypeptides with a compound that inhibits binding of p53 to XPB or XPD.

1           17 (previously presented): The method of claim 16, wherein the compound that  
2 inhibits binding of p53 to XPB or XPD is HBX.

1           18 (currently amended): The method of claim 1, further comprising  
2           (d) determining whether the compound suspected of inducing helicase-dependent  
3 p53-mediated apoptosis can inhibit helicase activity, wherein a compound that inhibits XPB or  
4 XPD helicase activity is a compound that modulates helicase- dependent p53-mediated  
5 apoptosis.

1                   19 (previously presented): The method of claim 18, wherein the helicase  
2 polypeptide is present as part of a TFIIH transcription complex.

1                   20 (previously presented): The method of claim 1, wherein the p53 polypeptide  
2 and the helicase polypeptide are each introduced into a cell.

1                   21 (previously presented): The method of claim 20, wherein at least one of the  
2 p53 polypeptide or the helicase polypeptide is a native polypeptide.

1                   22 (previously presented): The method of claim 20, wherein the p53 polypeptide  
2 is a wild-type p53 polypeptide.

1                   23 (previously presented): The method of claim 20, wherein the helicase  
2 polypeptide is a mutant helicase polypeptide.

1                   24 (previously presented): The method of claim 20, wherein the cell is a member  
2 selected from the group consisting of: a fibroblast cell, an epithelial cell, and a hematopoietic  
3 cell.